NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

You keep obfuscating. There have been Liau slides that have have the legend "ATL-DC (DCVax)" in the survival curves.

I believe you are talking about a slide on X that had ATL-DC as the lagend but had been edited by the X tweety to add DCVax. The slide from LL did not have that,

As far as the core subject, a few basic facts.

We know for a fact that UCLA and NWBO had different processes for making ATL-DCs back in the early 2000s. NWBO said so. NWBO said they might not be the same, so the FDA might force them to run a P1 with the NWBO version. And NWBO later did so.

We know as a fact that the ATL-DC in the Poly-ICLC combo trial used a different method of preparation. First, it used acid to extract the lysate from the tumor, while NWBO had always used freeze/thaw cycles. Second, the UCLA version prepared the ATl-DC just before use and injected fresh. The NWBO process saves money by running a single batch and freezing. In the world of biologics, these are very significant differences.

Third, LP has never referred to UCLA product as NWBO's DCVax-L, nor have they ever asserted any sort of ownership of that IP.

On the differences in the mfg method UCA used, see this paper on the ATL-DC P1 that is referenced from the combo trial paper
.

Fresh tumor samples from surgical resection were transported under sterile conditions to the UCLA Jonsson Cancer Center GMP facility and used to establish autologous primary glioblastoma multiforme cell lines, as previously described (27, 28). Cultured tumor cells were harvested and used for acid elution of surface peptides. The median duration of primary tumor cell culture was 5 weeks (range, 2-14 weeks).

On the day of each vaccination (study days 0, 14, and 28), cryopreserved dendritic cells were thawed, washed thrice, and pulsed 30 to 60 minutes with 100 µg of autologous glioblastoma multiforme tumor peptides in serum-free RPMI 1640

Very different from the NWBO DCVax-L process.